5alpha 17beta n 2 5 bis trifluoromethyl phenyl 3 oxo 4 azaandrost 1 ene 17 carboxamide, alpha alpha alpha alpha alpha alpha hexafluoro 3 oxo 4 aza 5alpha androst 1 ene 17beta carboxy 2 5 xylidide
For the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate gland to improve symptoms, and reduce the risk of acute urinary retention and ...